Discovery/R&D
-
Establishing Research With Horizon Therapeutics' Robert Stoffel, Ph.D.
7/26/2023
Horizon Therapeutics has made plenty of waves in the biotech news cycle of late. Its formal establishment of a research team – comparatively pragmatic as that may be – could have impactful, long-term consequences.
-
Plant-Based Biologics With iBio's Randy Maddux
2/14/2022
iBio COO Randy Maddux walks us through the Bryan, Texas-based biopharma's attempt to turn the CHO cell biologic development paradigm on its ear with hydroponically-grown N. benthamiana. His company's FastPharming approach to protein production, he says, could be modularized to speed cycle times and dramatically reduce upstream costs at scales large and small. For its part, iBio is proving out the approach on a host of therapeutic and vaccine candidates for oncological, infectious, and fibrotic diseases.
-
An AI Awakening With Profluent Bio's Hilary Eaton, Ph.D.
9/22/2024
Hilary Eaton, Ph.D. was a self-described AI skeptic, particularly regarding using the tool in drug discovery. Then, a series of professional and deeply personal life events and medical discoveries put her in a position to confront that skepticism head-on. On Business of Biotech, the Chief Business Officer at ProFluent Bio shares her story and makes a pragmatic case for the transformative value of AI to biotech builders.
-
Antibodies For Severe Allergies With IgGenix's Jessica Grossman, M.D.
4/4/2022
In this wide-ranging discussion, IgGenix CEO Jessica Grossman, M.D. discusses the application of and market opportunity for antibody therapy for severe allergies, the gender gap in the biopharma c-suite, why women work harder than men, what it means to be a female biopharma leader, and IgGenix's approach at isolating and re-engineering allergen-specific IgE antibodies into IgG antibodies designed to alleviate — and possibly prevent — allergic cascade.
-
Drug Development: From Bench To Bedside With Allan Shaw
5/10/2021
CFO to the biopharma stars and frequent Business of Biotech guest Allan Shaw joins us for a candid discussion on the keys to efficiency as you move your candidate from the bench to the bedside. Shaw shares the common perils of insular thinking in biopharma and offers practical advice for avoiding those pitfalls. We discuss the value of being early in the context of the current biopharma market — early to study, early to differentiate, early to kill if necessary, and early to fund your project on its journey to the clinic.
-
Turning The Liver Into A mAb Factory With Homology's Arthur Tzianabos, Ph.D.
11/15/2021
Homology Medicines' approaches to gene therapy and gene editing have the potential to seriously disrupt both the cell/gene therapy space \_and\_ the mAb manufacturing and administration paradigms as we know them. On this episode of the Business of Biotech, Homology President & CEO Arthur Tzianabos, Ph.D. shares the company's approach and supports its rationale for investing in its own development and manufacturing capacity.
-
Precision Drug Delivery with Ampersand Biomedicines' Jason Gardner, Ph.D.
4/10/2024
Ampersand Biomedicines CEO Jason Gardner, Ph.D. first took the leap from a global pharmaceutical giant to a startup at the forefront of transplant medicine innovation. Since that time, he's seen most of the ups and the downs that come with biotech leadership, and in his latest venture with the Flagship Pioneering-backed Ampersand, he's putting all those hard-fought lessons to good use.
-
AI-Driven Biologics With Fountain Therapeutics' William Greene, M.D
2/28/2022
With its hypothesis-free, target-free, AI-driven drug discovery platform, Fountain Therapeutics is turning the traditional drug discovery pathway on its ear to address a variety of age-related disease. On this week's episode of the Business of Biotech, Fountain CEO William Greene, M.D. joins us to discuss the approach, its rationale, and how the company is applying substantial support from the likes of Eli Lilly, Alexandria Venture Investments, R42 Group, Khosla Ventures, and Nan Fung Life Sciences.
-
Accelerating ADCs with Mythic Therapeutics' Brian Fiske, Ph.D.
5/26/2024
Mythic Therapeutics Chief Scientific Officer and Co-Founder Brian Fiske, Ph.D. broke some unwritten protocol with his rapid and multifaceted transition from academia to industry. He calls his many, and sometimes concurrent, early experiences as an MIT Ph.D. student, a Flagship Ventures Fellow, a Bain consultant, a hospital researcher, and a biopharma consultant indicative of a young man who didn't want to make decisions.
-
High-Throughput Discovery With BIOPTIC's Andrey Dobry
1/19/2025
Andrey "Dobry" Doronichev, the innovator who made YouTube mobile, is now revolutionizing biotech with his startup, BIOPTIC. In this episode of The Business of Biotech, Dobry explains how AI and advanced screening are reshaping drug discovery. Learn more about BIOPTIC’s bold vision, the challenges of data access, and overcoming skepticism in the biotech industry.